Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...

The implementation of Patents Act, as last amended in 2005, raises significant issues of immediate concern to patients across the world. INDIA'S Patents Act has an interesting history. Enacted first in 1911 as the Indian Patents and Designs Act in the colonial era, it primarily addressed the interests of inventors, who did not want their inventions infringed upon by anyone who copied them or adopted the methods used to make them....

-The Hindu   Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

According to the WHO, TB is the third leading cause of death for women aged 15-44 worldwide.   When did we last consider TB as one of India’s biggest health problems? To refresh memories, here are a few forgotten facts about TB in India: one of the leading causes of death in India, TB kills one person every two minutes and 750 people every day. The direct and indirect annual costs of...